These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 25855779)

  • 1. Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage.
    Tomlinson JA; Caplin B; Boruc O; Bruce-Cobbold C; Cutillas P; Dormann D; Faull P; Grossman RC; Khadayate S; Mas VR; Nitsch DD; Wang Z; Norman JT; Wilcox CS; Wheeler DC; Leiper J
    J Am Soc Nephrol; 2015 Dec; 26(12):3045-59. PubMed ID: 25855779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dimethylarginine Dimethylaminohydrolase 1 Deficiency Induces the Epithelial to Mesenchymal Transition in Renal Proximal Tubular Epithelial Cells and Exacerbates Kidney Damage in Aged and Diabetic Mice.
    Shi L; Zhao C; Wang H; Lei T; Liu S; Cao J; Lu Z
    Antioxid Redox Signal; 2017 Dec; 27(16):1347-1360. PubMed ID: 28594240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms.
    Caplin B; Nitsch D; Gill H; Hoefield R; Blackwell S; MacKenzie D; Cooper JA; Middleton RJ; Talmud PJ; Veitch P; Norman J; Wheeler DC; Leiper JM
    Kidney Int; 2010 Mar; 77(5):459-67. PubMed ID: 20010544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenoviral-mediated overexpression of DDAH improves vascular tone regulation.
    Torondel B; Nandi M; Kelly P; Wojciak-Stothard B; Fleming I; Leiper J
    Vasc Med; 2010 Jun; 15(3):205-13. PubMed ID: 20219849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of fluid reabsorption in rat or mouse proximal renal tubules by asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase 1.
    Bell T; Araujo M; Luo Z; Tomlinson J; Leiper J; Welch WJ; Wilcox CS
    Am J Physiol Renal Physiol; 2018 Jul; 315(1):F74-F78. PubMed ID: 29513072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine.
    Hu X; Atzler D; Xu X; Zhang P; Guo H; Lu Z; Fassett J; Schwedhelm E; Böger RH; Bache RJ; Chen Y
    Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1540-6. PubMed ID: 21493890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of lowering asymmetric dimethylarginine (ADMA) on vascular pathology in atherosclerotic ApoE-deficient mice with reduced renal mass.
    Jacobi J; Maas R; Arend M; Cordasic N; Hilgers KF
    Int J Mol Sci; 2014 Mar; 15(4):5522-35. PubMed ID: 24690995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency.
    Betz B; Möller-Ehrlich K; Kress T; Kniepert J; Schwedhelm E; Böger RH; Wanner C; Sauvant C; Schneider R
    Transl Res; 2013 Aug; 162(2):67-76. PubMed ID: 23707198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADMA reduction does not protect mice with streptozotocin-induced diabetes mellitus from development of diabetic nephropathy.
    Rodionov RN; Heinrich A; Brilloff S; Jarzebska N; Martens-Lobenhoffer J; Bode-Böger SM; Todorov VT; Hugo CPM; Weiss N; Hohenstein B
    Atheroscler Suppl; 2017 Nov; 30():319-325. PubMed ID: 29096857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is frequently upregulated in prostate cancer, and its overexpression conveys tumor growth and angiogenesis by metabolizing asymmetric dimethylarginine (ADMA).
    Reddy KRK; Dasari C; Duscharla D; Supriya B; Ram NS; Surekha MV; Kumar JM; Ummanni R
    Angiogenesis; 2018 Feb; 21(1):79-94. PubMed ID: 29150732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction.
    Xu X; Zhang P; Kwak D; Fassett J; Yue W; Atzler D; Hu X; Liu X; Wang H; Lu Z; Guo H; Schwedhelm E; Böger RH; Chen P; Chen Y
    Basic Res Cardiol; 2017 Aug; 112(5):55. PubMed ID: 28819685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA.
    Bulau P; Zakrzewicz D; Kitowska K; Leiper J; Gunther A; Grimminger F; Eickelberg O
    Am J Physiol Lung Cell Mol Physiol; 2007 Jan; 292(1):L18-24. PubMed ID: 16891395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of asymmetric dimethylarginine (ADMA) on heart failure development.
    Liu X; Hou L; Xu D; Chen A; Yang L; Zhuang Y; Xu Y; Fassett JT; Chen Y
    Nitric Oxide; 2016 Apr; 54():73-81. PubMed ID: 26923818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal asymmetric dimethylarginine inhibits fibrosis.
    Wu M; Yuan M; Wang Y; Tan B; Huang D; Wang C; Zou Y; Ye C
    FEBS Open Bio; 2020 Oct; 10(10):2003-2009. PubMed ID: 32794631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AGXT2 and DDAH-1 genetic variants are highly correlated with serum ADMA and SDMA levels and with incidence of coronary artery disease in Egyptians.
    Amir M; Hassanein SI; Abdel Rahman MF; Gad MZ
    Mol Biol Rep; 2018 Dec; 45(6):2411-2419. PubMed ID: 30284143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of alanine-glyoxylate aminotransferase 2 protects from asymmetric dimethylarginine-induced endothelial dysfunction and aortic remodeling.
    Rodionov RN; Jarzebska N; Burdin D; Todorov V; Martens-Lobenhoffer J; Hofmann A; Kolouschek A; Cordasic N; Jacobi J; Rubets E; Morawietz H; O'Sullivan JF; Markov AG; Bornstein SR; Hilgers K; Maas R; Pfluecke C; Chen Y; Bode-Böger SM; Hugo CPM; Hohenstein B; Weiss N
    Sci Rep; 2022 Jun; 12(1):9381. PubMed ID: 35672381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dimethylarginine dimethylaminohydrolase 1 modulates endothelial cell growth through nitric oxide and Akt.
    Zhang P; Hu X; Xu X; Chen Y; Bache RJ
    Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):890-7. PubMed ID: 21212404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia.
    Dayal S; Rodionov RN; Arning E; Bottiglieri T; Kimoto M; Murry DJ; Cooke JP; Faraci FM; Lentz SR
    Am J Physiol Heart Circ Physiol; 2008 Aug; 295(2):H816-25. PubMed ID: 18567702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlations of DDAH1 transcript variants with human endothelial asymmetric dimethylarginine metabolizing activity.
    Sun T; Zhou JP; Kuang DB; Li MP; Xiong Y; Tang J; Xia J; Bai YP; Yang GP; Li YJ; Chen XP
    Am J Hypertens; 2013 Dec; 26(12):1437-44. PubMed ID: 23864585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Cellularly Active Inhibitor Regresses DDAH1 Induced Prostate Tumor Growth by Restraining Tumor Angiogenesis through Targeting DDAH1/ADMA/NOS Pathway.
    Kami Reddy KR; Dasari C; Vandavasi S; Natani S; Supriya B; Jadav SS; Sai Ram N; Kumar JM; Ummanni R
    ACS Comb Sci; 2019 Apr; 21(4):241-256. PubMed ID: 30673277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.